Pharma Focus America
Thermo Fisher Scientific - Chemical Products

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Tuesday, April 04, 2023

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.

"Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "This newly available Noxafil® AG dosage form is the latest addition to our generics portfolio—providing patient access to high-quality, lower-cost treatment options."

Endo subsidiary Endo Ventures Limited entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, N.J. allowing Par to launch and distribute an authorized generic version of the product. The agreement also included the authorized generic version of Noxafil® delayed-release tablets, 100 mg, which launched in 2019.

Noxafil® is a registered trademark of Merck Sharp & Dohme LLC.



ROUQETTE - Pharma Virtual Lab